Trial Profile

An unblinded and without a control group phase Ib study assessing RMC-035 in patients undergoing kidney transplantation

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 19 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Jun 2023 Final results of this study confirming the previously positive preliminary data analysis and demonstrate favorable pharmacokinetic properties of RMC-035 without any serious adverse effects associated with the investigational drug, presented in a Guard Therapeutics media release.
16 Mar 2023 According to Guard Therapeutics media release, the study results enable determination of the appropriate dose range in a future efficacy study.
16 Mar 2023 According to Guard Therapeutics media release, Johan Nordstrom, consultant transplant surgeon at Karolinska University Hospital is the principal investigator of this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com